1.The Morbidity Trend of the Preterm Delivery in Thirty Years and Sampling Analysis of the Obsterical Factors
Minling CHEN ; Shunying HUANG ; Zilian WANG
Journal of Sun Yat-sen University(Medical Sciences) 2001;22(1):68-72
【Objective】 To investigate the morbidity trend of the preterm delivery.【Methods】 A retrospective study was done on the delivery data in our hospital from 1969 to 1998. Select the cases on annual August as the sam pling units, and divided those 253 cases into three decade groups, to analyze th e obsterical factors affecting the preterm delivery.【Results】 ① The morbidity of the preterm delivery in thirty years was 4.72%(95% CI 4.16, 5.32). ② The re were no obvious changes of the morbidity among the years, and had no seasonal aggregation. ③ The cesarean section rates in the third decade increased signif icantly than those in former two decades (P<0.05). ④ As time goes on, the i ncidence of premature rupture of membrane increased, and that of the preterm del ivery with no obvious complication decreased. The cases with the intrauterine fe tal distress and IVF-ET in the third decade were significantly increased. ⑤ Th e gestation age and birth weight increased significantly, especially in the thir d decade, but the neonatal mortality had no obvious change. 【Conclusions】 Ther e was no reduction of the morbidity of the preterm delivery, further studies sho uld be emphasized. It seems unlikely the increased of cesarean section rates wil l reduce the neonatal mortality. PROM is important factors affecting the preterm delivery, and the IVF women may be at higher risk of preterm delivery.
2.Efficacy of low energy 1064 nm Q-switched laser and intense pulsed light in treatment of facial post-inflammatory hyperpigmentation
Zilian HUANG ; Jing YANG ; Yuxue GAO
Chinese Journal of Medical Aesthetics and Cosmetology 2015;21(3):155-157
Objective To study the feasibility of joint phototherapy in the treatment of post-inflammatory hyperpigmentation and non-drug therapy in clinical popularization value of 1064 nm Qswitched laser in combination with low energy intense pulsed noncoherent light for secondary pigmentation.Methods A total of 128 patients with post-inflammatory hyperpigmentation were randomly divided into 3 groups according to different treatments:first group (42 cases) was subjected to low energy 1064 nm Q-switched laser treatment;second group (40 cases) had intense pulsed light treatment;third group (46 cases) had low energy 1064 nm Q-switched laser plus intense pulsed light therapy.Results After treating for 6 times,the effective rates of intense pulsed light and Q laser were 50% (20/40) and 52.4% (22/42),respectively,without statistical significance between two groups (P>0.05).Effective rate of the third group was 73.9% (34/46),with significant difference (P<0.05),compared with the first two groups.Conclusions For those who refuse any drug treatment,low energy 1064 nm Q-switched laser with intense pulsed light therapy is an effective option to facial postinflammatory hyperpigmentation.Furthermore,it has obvious and safe effect without complications and deserves popularization.
3.Progress in application of insulin analogues during pregnancy
Yihong HUANG ; Shaole SHI ; Zilian WANG
Chinese Journal of Perinatal Medicine 2022;25(10):776-780
Insulin analogues can reduce gestational hyperglycemia more safely and effectively because their molecular structure and metabolic characteristics are more consistent with the characteristics of gestational glucose metabolism. However, the safety and effectiveness of some insulin analogues in pregnancy remain unclear. At present, only a few insulin analogues, insulin aspart, insulin lispro and insulin detemir, have been approved for use during pregnancy in China. As for misuse or off-label insulin analogues during pregnancy, clinicians should make adjustments based on published clinical safety data. In this review, the safety and progress in the management of gestational hyperglycemia with rapid- and long-acting insulin analogues and insulin degludec/insulin aspart are reviewed to provide reference for insulin therapy during pregnancy.